Colin Love Sells 30,000 Shares of Replimune Group, Inc. (NASDAQ:REPL) Stock

Replimune Group, Inc. (NASDAQ:REPL) COO Colin Love sold 30,000 shares of the company’s stock in a transaction on Thursday, April 15th. The stock was sold at an average price of $30.63, for a total transaction of $918,900.00. Following the completion of the transaction, the chief operating officer now directly owns 898,509 shares of the company’s stock, valued at approximately $27,521,330.67. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Colin Love also recently made the following trade(s):

  • On Monday, March 15th, Colin Love sold 30,000 shares of Replimune Group stock. The shares were sold at an average price of $33.54, for a total value of $1,006,200.00.
  • On Tuesday, February 16th, Colin Love sold 30,000 shares of Replimune Group stock. The shares were sold at an average price of $36.32, for a total value of $1,089,600.00.
  • On Tuesday, January 19th, Colin Love sold 7,857 shares of Replimune Group stock. The stock was sold at an average price of $42.46, for a total value of $333,608.22.

REPL stock opened at $28.50 on Wednesday. The firm has a market cap of $1.33 billion, a PE ratio of -16.10 and a beta of 2.63. The firm has a fifty day moving average price of $32.38 and a 200 day moving average price of $39.07. The company has a debt-to-equity ratio of 0.13, a quick ratio of 19.47 and a current ratio of 19.47. Replimune Group, Inc. has a fifty-two week low of $10.62 and a fifty-two week high of $54.85.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings data on Thursday, February 4th. The company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.03). On average, equities analysts predict that Replimune Group, Inc. will post -1.73 EPS for the current year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD raised its position in Replimune Group by 516.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,625,691 shares of the company’s stock valued at $100,170,000 after purchasing an additional 2,199,530 shares during the period. BlackRock Inc. raised its position in Replimune Group by 44.2% in the 4th quarter. BlackRock Inc. now owns 2,176,096 shares of the company’s stock worth $83,019,000 after purchasing an additional 667,249 shares during the period. Emerald Mutual Fund Advisers Trust lifted its stake in Replimune Group by 4.0% in the fourth quarter. Emerald Mutual Fund Advisers Trust now owns 856,603 shares of the company’s stock worth $32,679,000 after purchasing an additional 32,614 shares during the last quarter. Norges Bank bought a new position in shares of Replimune Group during the fourth quarter valued at approximately $28,681,000. Finally, Morgan Stanley boosted its holdings in shares of Replimune Group by 9,787.9% in the fourth quarter. Morgan Stanley now owns 373,466 shares of the company’s stock valued at $14,248,000 after purchasing an additional 369,689 shares during the period. Institutional investors own 55.79% of the company’s stock.

A number of research analysts recently commented on REPL shares. Zacks Investment Research cut Replimune Group from a “buy” rating to a “hold” rating in a report on Friday, January 8th. SVB Leerink reduced their price objective on shares of Replimune Group from $57.00 to $56.00 and set an “outperform” rating on the stock in a research report on Thursday, February 4th. Finally, HC Wainwright upped their target price on shares of Replimune Group from $58.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, February 5th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $52.78.

Replimune Group Company Profile

Replimune Group, Inc, a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma.

See Also: What factors cause inflation to rise?

Insider Buying and Selling by Quarter for Replimune Group (NASDAQ:REPL)

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.